[Efficacy and safety of boceprevir based triple therapy in Hungarian patients with hepatitis C genotype 1 infection, advanced stage fibrosis and prior treatment failure].
CONCLUSIONS: With boceprevir based triple therapy, one of the bests available in 2011-2013 in Hungary, a relevant proportion of hepatitis C infected patients with advanced liver fibrosis achieved sustained viral response. In this cohort, side-effects resembled those reported in registration studies, and resulted in therapy discontinuation with consequent treatment failure in a relevant number of patients. Efficacy and tolerability of boceprevir-based triple therapy are suboptimal, particularly in the most difficult to cure patient population. Orv. Hetil., 2016, 157(34), 1366-1374.
PMID: 27546804 [PubMed - in process]
Source: Orvosi Hetilap - Category: Journals (General) Authors: Hunyady B, Abonyi M, Csefkó K, Gervain J, Haragh A, Horváth G, Jancsik V, Makkai E, Müller Z, Ribiczey P, Sipos B, Szabó O, Szalay F, Szentgyörgyi L, Tornai I, Újhelyi E, Varga M, Weisz G, Makara M Tags: Orv Hetil Source Type: research
More News: Anemia | Campylobacter | Crohn's Disease | Depression | Dermatitis | Dermatology | Diarrhoea | Gastroenteritis | General Medicine | Gingivitis | Hepatitis | Hepatitis C | Hungary Health | Inflammatory Bowel Disease | Liver | Study | Urology & Nephrology | Virology